Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma. Their study was published this month in the journal Blood Neoplasia.
A team of researchers developed a best practice framework that other researchers and health systems can leverage to build trustworthiness and increase diversity in biospecimen research.
